Ernexa Therapeutics (ERNAW) Receivables (2010 - 2025)

Ernexa Therapeutics (ERNAW) has 16 years of Receivables data on file, last reported at -$58000.0 in Q4 2025.

• Quarterly Receivables fell 123.2% year-over-year to -$58000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$58000.0 (down 123.2% YoY) and the FY2025 annual result came in at $750000.0, up 71.62% from the prior year.
• Receivables retreated to -$58000.0 in Q4 2025, from $250000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.3 million in Q4 2021 to a low of -$1.4 million in Q4 2023.
• A 5-year average of $38986.3 and a median of $22959.0 in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2021 — Receivables surged 1103.57% — and 2023, when it sank 5508.0%.
• Tracing ERNAW's Receivables over 5 years: stood at $1.3 million in 2021, then sank by 98.15% to $25000.0 in 2022, then slumped by 5508.0% to -$1.4 million in 2023, then soared by 118.49% to $250000.0 in 2024, then plunged by 123.2% to -$58000.0 in 2025.
• The last three Receivables figures came in at -$58000.0 (Q4 2025), $250000.0 (Q4 2024), and -$1.4 million (Q4 2023), per Business Quant data.